

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	10/643,743
Filing Date	August 19, 2003
First Named Inventor	Réal Lemieux et al.
Art Unit	1645
Examiner Name	Not yet known
Attorney Docket Number	701826-054340

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date
Considered

9127106

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/643,743
				Filing Date	August 19, 2003
				First Named Inventor	Réal Lemieux et al.
				Art Unit	1645
				Examiner Name	Not yet known
Sheet	2	of	4	Attorney Docket Number	701826-054340

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
B31	C1	Adib M, Ragimbeau J, Avrameas S, Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol. 1990;145:3807-3813	
	C2	Avrameas S, Ternynck T. The natural autoantibodies system: between hypotheses and facts. Mol Immunol. 1993;30:1133-1142	
	C3	Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc. 2002;42:449-459	
	C4	Berneman A, Guilbert B, Eschrich S, Avrameas S. IgG auto- and polyreactivities of normal human sera. Mol Immunol. 1993;30:1499-1510	
B35	C5	Dahl MV, Bridges AG. Intravenous immune globulin: fighting antibodies with antibodies. J Am Acad Dermatol. 2001;45:775-783	
	C6	Dietrich G, Algiman M, Y S, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood. 1992;79:2946-2951	
	C7	Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, Spaeth PJ, Neftel KA. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. AmJ Hematol. 2001;68:4-10	
	C8	Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenia purpura by high-dose intravenous gamma globulin. N Eng J Med. 1982;306:1254-1258	
	C9	Hadley AG, Kumpel BM, Merry AH. The chemiluminescent response of human monocytes to red cells sensitized with monoclonal anti-Rh(D) antibodies. Clin Lab Haematol. 1988;10:377-384	
	C10	Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Eng J Med. 2001;345:747-755	

Examiner Signature		Date Considered	9/27/06
--------------------	--	-----------------	---------

*EXAMINER If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/643,743
				Filing Date	August 19, 2003
				First Named Inventor	Réal Lemieux et al.
				Art Unit	1645
				Examiner Name	Not yet known
Sheet	3	of	4	Attorney Docket Number	701826--054340

MS	C11	Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVig) can lead to enhanced erythrocyte sequestration. J Autoimmun. 1999;13:129-135	
I	C12	Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous immunoglobulin. J Immunol. 1984;132:745-750	
↓	C13	Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayoub A, Evelyne M, Coutinho A, Kazatchkine MD. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods. 1998;216:117-137	
MS	C14	Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. Biodrugs. 2002;16:47-55	
I	C15	Lazarus AH, Freedman J, Semple JW. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenia purpura (ITP): mechanisms of action. Transfus Sci. 1998;19:289-294	
I	C16	Lock RJ, Unsworth DJ. Measurement of immune complexes is not useful in routine clinical practice. Ann Clin Biochem. 2000;37:253-261	
↓	C17	Louzir H, Ternynck T, Gorgi Y, Ayed K, Avrameas S. Enzyme immunoassay analysis of antibody specificities present in the circulating immune complexes of selected pathological sera. J Immunol Methods. 1988;114:145-153	
MS	C18	Matejtschuk P, Chidwick K, Prince A, More JE, Goldblatt E. A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donors plasmas. Vox Sang. 2002;83:17-22	
I	C19	Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA. Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenia purpura-prone (NZW x BXSB) F1 mice. Blood. 1993;82:837-844	
I	C20	Ohlson S, Zetterstrand K. Detection of circulating immune complexes by PEG precipitation combined with ELISA. J Immunol Methods. 1985;77:87-93	
↓	C21	Rossi F, Guilbert B, Tonnel C, Ternynck T, Fumoux F, Avrameas S, Kazatchkine MD. Idiotype interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol. 1990;20:2089-2094	

Examiner Signature		Date Considered	9/27/06
--------------------	---	-----------------	---------

*EXAMINER If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/643,743
				Filing Date	August 19, 2003
				First Named Inventor	Réal Lemieux et al.
				Art Unit	1645
				Examiner Name	Not yet known
Sheet	4	of	4	Attorney Docket Number	701826-054340

131	C22	Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science. 2001;291:484-486	
131	C23	Theofilopoulos AN. The Raji, conglutinin, and anti-C3 assays for the detection of complement-fixing immune complexes. Methods Enzymol. 1981;74:511-530	
	C24	Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995;8:405-413	
	C25	Vassilev TL et al., "Inhibition of cell adhesion by antibodies to Arg-Gly-Asp(RGD) in normal immunoglobulin for therapeutic use..." BLOOD, W. B. SAUNDERS COMPANY vol. 93, no. 11, 1999, pages 3624-3631	
	C26	Kaveri Srin et al. "Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in..." Journal of Clinical Investigation, vol. 97, no. 3, 1996, pages 865-869.	


Examiner Signature		Date Considered	9/27/06
--------------------	--	-----------------	---------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A/B 08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Substitute for form 1449 PTO		Complete if Known	
		Application Number		10/643,743	
		Filing Date		08/19/2003	
		First Named Inventor		Lemieux. R.	
		Art Unit		1645	
		Examiner Name		To be assigned	
Sheet	1	of	1	Attorney Docket Number	701826-054340

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ²
W	B2	EP 1 059 088 A1	12-13-2000	Bouvet et al		X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²

Examiner Signature		Date Considered	9/27/06
-----------------------	--	--------------------	---------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.